BRCA2 and neoplasm: It is also approved as a maintenance therapy after response to platinum-based chemotherapy for ovarian cancer, indicating benefit from PARP inhibition beyond tumours with BRCA1/2 mutations.8, 9 Furthermore, olaparib has antitumour activity in vitro and in vivo in models that are defective in other DDR proteins, including PALB2, ATM, FANCD2, RAD51, and RAD54, among others, although the magnitude of preclinical sensitisation varies between proteins, with BRCA2 loss being arguably the most potent sensitising event.10, 11